Burning Rock Biotech (Burning Rock Biotech) Gross Margin % : 64.51% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Burning Rock Biotech Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Burning Rock Biotech's Gross Profit for the three months ended in Dec. 2023 was $10.94 Mil. Burning Rock Biotech's Revenue for the three months ended in Dec. 2023 was $16.96 Mil. Therefore, Burning Rock Biotech's Gross Margin % for the quarter that ended in Dec. 2023 was 64.51%.

The historical rank and industry rank for Burning Rock Biotech's Gross Margin % or its related term are showing as below:

BNR' s Gross Margin % Range Over the Past 10 Years
Min: 64.49 Med: 67.59 Max: 73.02
Current: 67.6

During the past 7 years, the highest Gross Margin % of Burning Rock Biotech was 73.02%. The lowest was 64.49%. And the median was 67.59%.

BNR's Gross Margin % is ranked better than
78.04% of 214 companies
in the Medical Diagnostics & Research industry
Industry Median: 46.155 vs BNR: 67.60

Burning Rock Biotech had a gross margin of 64.51% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Burning Rock Biotech was 0.10% per year.

Burning Rock Biotech Gross Margin % Historical Data

The historical data trend for Burning Rock Biotech's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burning Rock Biotech Gross Margin % Chart

Burning Rock Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

71.61

73.02

71.70

67.47

67.59

Burning Rock Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															71.19	69.31	68.66	67.35	64.51

Competitive Comparison of Burning Rock Biotech's Gross Margin %

For the Diagnostics & Research subindustry, Burning Rock Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Burning Rock Biotech's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's Gross Margin % falls into.

Burning Rock Biotech Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Burning Rock Biotech's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	50.9	/	75.269
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(75.269 - 24.398)	/	75.269
	=	67.59 %

Burning Rock Biotech's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	10.9	/	16.958
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(16.958 - 6.018)	/	16.958
	=	64.51 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Burning Rock Biotech (NAS:BNR) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Burning Rock Biotech had a gross margin of 64.51% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Burning Rock Biotech Gross Margin % Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Burning Rock Biotech (Burning Rock Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

BNR:UK 6BUA:Germany

Address

No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005

Website

https://www.brbiotech.com

Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.